石藥集團(01093.HK)"鹽酸多奈哌齊片"獲藥品註冊批件
格隆匯5月5日丨石藥集團(01093.HK)公吿,公司附屬公司石藥集團歐意藥業有限公司開發的"鹽酸多奈哌齊片(5mg、10mg)"("該產品")已獲得中華人民共和國國家藥品監督管理局頒發藥品註冊批件,並視同通過仿製藥質量和療效一致性評價。
鹽酸多奈哌齊片用於輕度、中度或重度阿爾茨海默病症狀的治療。目前認為阿爾茨海默病痴呆症狀的發病機制部分與膽礆能神經傳遞功能的低下有關。鹽酸多奈哌齊可能通過增強膽礆能神經的功能發揮治療作用,它可逆性地抑制乙酰膽礆酯酶對乙酰膽礆的水解,從而提高乙酰膽礆的濃度。
該產品的獲批將進一步豐富集團在精神神經疾病的產品組合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.